Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

- PMLiVE

Lundbeck revenues fall on Lexapro competition

Reinforces need for successful vortioxetine launch

- PMLiVE

Watson completes Actavis acquisition, will rebrand in 2013

Will bring its global operations under the Actavis name from next year

- PMLiVE

India revokes Roche’s Pegasys patent after patient group challenge

Company becomes latest in big pharma to see intellectual property overturned

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

GSK sales drop as austerity measures hit business in Europe

Revenues in region drop 9 per cent

- PMLiVE

BMJ to only publish trials with open data

Comes as journal pushes Roche for full data on Tamiflu

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

Bristol-Myers Squibb (BMS) building

BMS slides to loss as Plavix revenues dry up

Records net loss of $711m during third quarter

Roche - Basel

EMA launches probe into Roche’s adverse event reporting

Pharma company allegedly failed to follow pharmacovigilance procedures

- PMLiVE

Abbott and Seattle expand antibody-drug conjugate collaboration

Pharma company could pay $220m per oncology target

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links